Tous Actualités
Suivre
Abonner SYGNIS AG

SYGNIS AG

euro adhoc: LION bioscience AG
Strategic management decisions
LION bioscience sells bioinformatics business, Dr. Thure Etzold resigns as CEO

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
04.04.2006
Ad-hoc Release
LION bioscience sells bioinformatics business
Dr. Thure Etzold resigns as CEO
Heidelberg, April 4, 2006 - LION bioscience AG today  announced  the
successful completion of the sales process regarding its
bioinformatics business.
As of April 4, 2006 the bioinformatics business, consisting of the
subsidiaries LION Bioscience  Ltd,  Cambridge  UK  and  LBAV  Inc.,
Cambridge,  MA,  USA  is transferred to BioWisdom Ltd., Cambridge,
UK. The sales price is up to 4 Mio  E.
In this context, Dr. Thure Etzold, original inventor of the SRS
technology  and current CEO of LION, will resign from the LION board
as  of  April  4,  2006  as planned.
For further information, please contact:
|Peter Willinger                        |
|Chief Financial Officer                |
|Tel: +49 (0) 6221-4038 293             |
|Email:                                 |
|peter.willinger@lionbioscience.com     |
Except for the historical information contained herein, the  matters
set  forth in this press release are forward looking. These
forward-looking statements  may include  projections,  assumptions,
estimates,  targets,  and  descriptions  of future events. Such
statements are based on currently available information  and on
LION's current expectations as to future events that  may  not  prove
to  be accurate. These statements are not guarantees of future
performance and  involve risks and uncertainties that are difficult
to predict. Many factors could  cause the actual results,
performance  or  achievements  of  LION  to  be  materially different
from those that may be projected,  expected,  targeted,  expressed
or implied by such statements. All roll-out plans and future dates
with respect  to completion of development and market release of LION
products are  target  dates only based on the company's current
planning and may change in the  future.  Any delays in the current
product release schedule will have  a  materially  adverse effect on
the company's targets for fiscal year. ###
end of announcement                               euro adhoc 04.04.2006 15:11:53

Further inquiry note:

Stephan Trautvetter
Director Finance & Accounting
Telefon: +49(0)6221 4038 476
E-Mail: stephan.trautvetter@lionbioscience.com

Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime
standard
New York / ADR
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade

Plus de actualités: SYGNIS AG
Plus de actualités: SYGNIS AG